Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia

Qiuyu Guo, Ye-Jun Wu, Gao-Chao Zhang, Yu-Xiu Chen, Meng-Lin Li, Meng-Yu Xiao, Jian-Ying Zhou, Lu-Lu Wang, Meng-Tong Zang, Zhuo-Yu An, Hai-Xia Fu, Xiao-Jun Huang, Xiao-Hui Zhang

Blood (2024) 144 (Supplement 1): 425.

https://doi.org/10.1182/blood-2024-203555

Published: 2024

Journal Articles

Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases

Zhu Li, Yaling Zheng, Huanyu Wang, Chao Zhang, Li Liu, Lulu Lv, Li Zhou

Blood (2024) 144 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2024-199874

Published: 2024

Journal Articles

Development of a Novel Allogeneic Super -Γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors

Hanlu Wang, Li Liu, Chao Zhang, Junxiao Gao, Lulu Lv, Li Zhou

Blood (2024) 144 (Supplement 1): 2058.

https://doi.org/10.1182/blood-2024-201322

Published: 2024

Journal Articles

Identification of LPAR1/LPAR5 As Novel GPCR Partners of GPRC5D for the Efficient CAR-T Therapy of Multiple Myeloma

Xinyi Zhou, Ying Yang, Xiaoli Hu, Tiancheng Luo, Shangrun Liu, Chao Zhang, Juan Du

Blood (2023) 142 (Supplement 1): 4679.

https://doi.org/10.1182/blood-2023-186150

Published: 2023

Journal Articles

BGS-2456 Is a Novel Potent Covalent Inhibitor of FLT3 That Highly Discriminates Against KIT and Is Not Toxic Toward Normal Hematopoiesis in Vitro

Ariel Leyte-Vidal, Stacey Phan, Prachi Khare, FeiFei Hu, Chao Zhang, Ping Cao, Neil P. Shah

Blood (2023) 142 (Supplement 1): 2265.

https://doi.org/10.1182/blood-2023-173116

Published: 2023

Journal Articles

Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia

Xu Beilei, Chao Zhang, Junxiao Gao, Zhu Li, Shengzhen Ding, Li Liu, Hang Zhang, Lulu Lyu, Li Zhou

Blood (2023) 142 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2023-173608

Published: 2023

Journal Articles

Targeting the JAK2V617F Hematopoietic Stem Cell through Beta1 Integrin

Shinobu Matsuura, Siyang Long, Iris Karkempetzaki, Aikaterini Karagianni, Xiaosheng Yang, Nasi Huang, Yuchen Liu, Chao Zhang, Katya Ravid

Blood (2023) 142 (Supplement 1): 4517.

https://doi.org/10.1182/blood-2023-186090

Published: 2023

Journal Articles

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Alice S. Mims, Melhem Solh, Jennifer N. Saultz, Uma Borate, Naveen Pemmaraju, Gautam Borthakur, Gail J. Roboz, Ben Powell, Bernice Matusow, Jason Halladay, Shireen Vali, Chelsea L. Hope, Madan G. Kundu, Ching Hsu, Paul Watkins, Chao Zhang, Jackie M. Walling, Athanasios C. Tsiatis, Amy E. DeZern

Blood (2021) 138 (Supplement 1): 3420.

https://doi.org/10.1182/blood-2021-152040

Published: 2021

Journal Articles

Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib By Increasing TSP-1-Dependent TGF-β1 Activation in Bone Marrow

Chao Zhang, Xiaoxuan Xu, Timothy Trotter, Amjad Javed, Joanne E. Murphy-Ullrich, Juan Li, Yang Yang

Blood (2021) 138 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2021-149310

Published: 2021

Journal Articles

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Alice S. Mims, MD, Melhem Solh, MD, Uma Borate, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Gail J. Roboz, MD, Ben Powell, PhD, Paul Severson, PhD, Bernice Matusow, Jason Halladay, PhD, Ching Hsu, PhD, Paul Watkins, Chao Zhang, PhD, Jackie M. Walling, PhD MD, Athanasios C. Tsiatis, MD, Amy E. DeZern, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-140138

Published: 2020

Journal Articles

Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR + and αvβ3 + Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT

Feng-qi Liu, Fei-er Feng, Gao-chao Zhang, Yan Su, Xue-yan Sun, Qiu-sha Huang, Qi Chen, Xiao Liu, Yun He, Xiao-lu Zhu, Hai-xia Fu, Kai-yan Liu, Xiao-hui Zhang

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-137115

Published: 2020

Journal Articles

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Heng Pan, PhD, Loïc Renaud, MD MSc, Ronan Chaligne, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Daniel Mertens, PhD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Chao Zhang, PhD, Doron Betel, PhD, Andreas Gnirke, Marcin Imielinski, Jerome Moreaux, PhD, Michael Hallek, Alexander Meissner, PhD, Stephan Stilgenbauer, MD, Catherine J. Wu, MD, Olivier Elemento, PhD, Dan A. Landau, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136830

Published: 2020

Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 1373.

https://doi.org/10.1182/blood-2019-124030

Published: 2019

Journal Articles

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Naveen Pemmaraju, MD, Uma Borate, MD, Melhem Solh, MD, Gautam M. Borthakur, MD, Amy E. DeZern, MD, Chao Zhang, PhD, Ben Powell, PhD, Paul Severson, Kerry Inokuchi, Bernice Matusow, Jason Halladay, Ching Hsu, PhD, Paul Watkins, Jackie M. Walling, PhD MD, Athanasios C. Tsiatis, MD, Alice S. Mims, MD

Blood (2019) 134 (Supplement_1): 1391.

https://doi.org/10.1182/blood-2019-127497

Published: 2019

Journal Articles

Arsenic Trioxide Encapsulated in MSC-Derived Extracellular Vesicles: A Novel Therapy for aGVHD in Mice

Xiao Liu, Ya-Nan Wang, Gao-chao Zhang, Yan Su, MD, Qiu-sha Huang, Chen-Cong Wang, Hai-Xia Fu, Yun He, Qian-Ming Wang, Xiang-Yu Zhao, Xiao-Su Zhao, Meng Lv, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiaohui Zhang, MD

Blood (2018) 132 (Supplement 1): 5673.

https://doi.org/10.1182/blood-2018-99-114904

Published: 2018

Journal Articles

A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations

Jack Lin, PhD, Ying Zhang, PhD, Bernice Matusow, Adam Mumy, Garson Tsang, Jiazhong Zhang, PhD, Hannah Powers, Wayne Spevak, PhD, Paul Severson, PhD, James Tsai, Gideon Bollag, PhD, Chao Zhang, PhD

Blood (2016) 128 (22): 1074.

https://doi.org/10.1182/blood.V128.22.1074.1074

Published: 2016

Journal Articles

Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers

Yasmine N White, Aditi Bagchi, Jessica Van Ziffle, PhD, Gideon Bollag, PhD, Chao Zhang, PhD, David S Dickens, MD, Mignon L. Loh, MD, Kevin Shannon, MD, Ari J Firestone, PhD

Blood (2014) 124 (21): 2207.

https://doi.org/10.1182/blood.V124.21.2207.2207

Published: 2014

Journal Articles

The Combination of PLX3397, a Selective FLT3-ITD Inhibitor, and Decitabine, a Hypomethylating Agent, Demonstrates Benefit in AML Cell Lines in Vitro and in Vivo

James Tsai, Elizabeth A Burton, PhD, Gaston Habets, PhD, Brian West, PhD, Paul Lin, MD, Henry Hsu, MD, Chao Zhang, PhD, Gideon Bollag, PhD

Blood (2014) 124 (21): 3743.

https://doi.org/10.1182/blood.V124.21.3743.3743

Published: 2014

Journal Articles

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Catherine C Smith, MD, Kimberly Lin, BS, Elisabeth Lasater, PhD, Whitney Stewart, BS, Lauren E Damon, Andrew Kasarskis, PhD, Ali Bashir, PhD, Matthew Pendleton, Robert Sebra, Alexander E Perl, MD, Mai H Le, MD, Chao Zhang, PhD, Brian West, Ph.D., Neil P. Shah, MD, PhD

Blood (2013) 122 (21): 3938.

https://doi.org/10.1182/blood.V122.21.3938.3938

Published: 2013

Journal Articles

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo

Angell Shieh, Ashley F. Ward, Kegan L. Donlan, Emily R. Harding-Theobald, Jin Xu, Charles G. Mullighan, Chao Zhang, Shann-Ching Chen, Xiaoping Su, James R. Downing, Gideon E. Bollag, Kevin M. Shannon

Blood (2013) 121 (24): 4884–4893.

https://doi.org/10.1182/blood-2012-05-432252

Published: 2013

Includes: Supplemental data

NARROW

β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia

Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases

Development of a Novel Allogeneic Super -Γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors

Identification of LPAR1/LPAR5 As Novel GPCR Partners of GPRC5D for the Efficient CAR-T Therapy of Multiple Myeloma

BGS-2456 Is a Novel Potent Covalent Inhibitor of FLT3 That Highly Discriminates Against KIT and Is Not Toxic Toward Normal Hematopoiesis in Vitro

Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia

Targeting the JAK2V617F Hematopoietic Stem Cell through Beta1 Integrin

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib By Increasing TSP-1-Dependent TGF-β1 Activation in Bone Marrow

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR + and αvβ3 + Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT

Robust Discovery of Candidate DNA Methylation Cancer Drivers

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Arsenic Trioxide Encapsulated in MSC-Derived Extracellular Vesicles: A Novel Therapy for aGVHD in Mice

A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations

Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers

The Combination of PLX3397, a Selective FLT3-ITD Inhibitor, and Decitabine, a Hypomethylating Agent, Demonstrates Benefit in AML Cell Lines in Vitro and in Vivo

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only